⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Gedeon Richter Plc. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Gedeon Richter Plc.
↗Budapest, Hungary
Gedeon Richter Plc. is a major Hungarian multinational pharmaceutical and biotechnology company, recognized as the largest pharmaceutical manufacturer in Central and Eastern Europe. Founded in 1901, the company maintains a vertically integrated business model that encompasses original research, development, manufacturing, and a global sales network.
The company specializes in Women's Healthcare, Central Nervous System (CNS) disorders, and the development of biosimilars. It is globally noted for the discovery of Cariprazine (Vraylar/Reagila), a blockbuster antipsychotic medication developed in partnership with AbbVie.
CLASSIFICATION
Company Type:Pharma
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:Women's Health, CNS, Biosimilars
SIZE & FINANCIALS
Employees:10000+
Revenue:$2.6B
Founded:1901
Ownership:public
Status:operating
STOCK
Exchange:Budapest Stock Exchange
Ticker:RICHTER
Market Cap:$7.2B
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Small molecule, Recombinant biotechnology, Biosimilars
Active Trials:130
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Helm BioTec, Medimpex, Preglem
Key Partnerships:AbbVie (Co-development of Cariprazine)
COMPETITION
Position:Leader
LEADERSHIP
Key Executives:
Gábor Orbán - CEO
Erik Bogsch - Chairman
LINKS
Website:gedeonrchter.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Gedeon Richter Plc.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.